248 related articles for article (PubMed ID: 34886831)
1. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
[TBL] [Abstract][Full Text] [Related]
2. Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
Fukushima J Med Sci; 2022 Apr; 68(1):1-10. PubMed ID: 35197393
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study.
Tetsunaga T; Tetsunaga T; Nishida K; Misawa H; Takigawa T; Yamane K; Tsuji H; Takei Y; Ozaki T
J Orthop Surg Res; 2020 May; 15(1):191. PubMed ID: 32456647
[TBL] [Abstract][Full Text] [Related]
6. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
Dahan L; Williet N; Le Malicot K; Phelip JM; Desrame J; Bouché O; Petorin C; Malka D; Rebischung C; Aparicio T; Lecaille C; Rinaldi Y; Turpin A; Bignon AL; Bachet JB; Seitz JF; Lepage C; François E;
J Clin Oncol; 2021 Oct; 39(29):3242-3250. PubMed ID: 34288696
[TBL] [Abstract][Full Text] [Related]
8. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
9. Folfirinox chemotherapy prolongs stent patency in patients with malignant biliary obstruction due to unresectable pancreatic cancer.
Kang J; Lee SH; Choi JH; Paik WH; Ahn DW; Jeong JB; Ryu JK; Kim YT
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):590-595. PubMed ID: 32532598
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Park H; Jin RU; Wang-Gillam A; Suresh R; Rigden C; Amin M; Tan BR; Pedersen KS; Lim KH; Trikalinos NA; Acharya A; Copsey ML; Navo KA; Morton AE; Gao F; Lockhart AC
JAMA Oncol; 2020 Aug; 6(8):1231-1240. PubMed ID: 32469386
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study.
Yokoyama S; Nakagawa C; Hosomi K
Support Care Cancer; 2022 Feb; 30(2):1765-1773. PubMed ID: 34595605
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRINOX goes adjuvant.
Romero D
Nat Rev Clin Oncol; 2019 Mar; 16(3):145. PubMed ID: 30659285
[No Abstract] [Full Text] [Related]
13. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
[TBL] [Abstract][Full Text] [Related]
14. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
[TBL] [Abstract][Full Text] [Related]
15. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
Hsu HT; Wu LM; Lin PC; Juan CH; Huang YY; Chou PL; Chen JL
Medicine (Baltimore); 2020 Feb; 99(6):e19029. PubMed ID: 32028414
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol.
Jang CE; Jung MS; Sohn EH; Kim M; Yoo HS; Bae K; Kim JR; Lee JS
Trials; 2018 Sep; 19(1):526. PubMed ID: 30268158
[TBL] [Abstract][Full Text] [Related]
17. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Tong H; Fan Z; Liu B; Lu T
Sci Rep; 2018 Jun; 8(1):8666. PubMed ID: 29875415
[TBL] [Abstract][Full Text] [Related]
18. Comparative analgesic efficacy of pregabalin administered according to either a prevention protocol or an intervention protocol in rats with cisplatin-induced peripheral neuropathy.
Han FY; Kuo A; Nicholson JR; Corradinni L; Smith MT
Clin Exp Pharmacol Physiol; 2018 Oct; 45(10):1067-1075. PubMed ID: 29781509
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study.
Ye LF; Ren C; Bai L; Liang JY; Hu MT; Yang H; Wang ZQ; Wang FH; Xu RH; Li YH; Wang DS
Invest New Drugs; 2021 Jun; 39(3):836-845. PubMed ID: 33411209
[TBL] [Abstract][Full Text] [Related]
20. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
[No Abstract] [Full Text] [Related]
[Next] [New Search]